Norwich Loses US Vyvanse Appeal – But Patents Run Course In August

Blockbuster ADHD Drug Set To Face Competition, 16 Years Post Launch

 
• By Dean Rudge

US-based Norwich Pharmaceuticals has lost its bid to move several months early on US competition to Takeda’s Vyvanse ADHD blockbuster.

Young boy holds ADHD text written on sheet of paper. ADHD is Attention deficit hyperactivity disorder. Close up. - Image
• Source: Shutterstock

More from Legal & IP

More from Generics Bulletin